Photopheresis for early skin involvement in systemic sclerosis
Part of Skin clinical trials.
This trial studies whether extracorporeal photopheresis can calm disease activity in people with early diffuse skin systemic sclerosis. If you qualify, you would receive this treatment in hopes of improving active skin disease and reducing inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent
- You have systemic sclerosis (SSc) confirmed by the study’s standard criteria
- Your skin disease is early (within 5 years of first non–Raynaud’s symptom) or you have active disease signs
- Your disease activity is supported by at least one marker (skin score ≥15, tendon “friction rubs,” or inflammation blood tests), not from infection or lung scarring from SSc
- Your breathing tests and scans are safe enough (not too weak lungs, and no significant pulmonary hypertension)
- You cannot have several key exclusions like uncontrolled heart/lung disease, active infections (including TB/viral hepatitis flare), low platelets, severe anemia, or prior photopheresis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a follow-up study that keeps studying Adcetris (brentuximab vedotin) in people with worsening diffuse cutaneous systemic sclerosis (dcSSc) who were in an earlier Adcetris study. It aims to see if the treatment continues to help your skin symptoms over time and stays safe.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.